Raymond James Financial Inc. Makes New Investment in Stevanato Group S.p.A. (NYSE:STVN)

Raymond James Financial Inc. bought a new position in shares of Stevanato Group S.p.A. (NYSE:STVN - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 264,084 shares of the company's stock, valued at approximately $5,754,000. Raymond James Financial Inc. owned 0.09% of Stevanato Group at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. M&T Bank Corp acquired a new position in shares of Stevanato Group during the 4th quarter worth $572,000. US Bancorp DE grew its position in Stevanato Group by 17.9% during the fourth quarter. US Bancorp DE now owns 8,527 shares of the company's stock worth $186,000 after buying an additional 1,295 shares during the period. Mutual of America Capital Management LLC purchased a new position in Stevanato Group in the fourth quarter valued at about $13,848,000. Oppenheimer Asset Management Inc. lifted its position in shares of Stevanato Group by 9.7% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 12,874 shares of the company's stock valued at $281,000 after acquiring an additional 1,141 shares during the period. Finally, Van Berkom & Associates Inc. purchased a new stake in shares of Stevanato Group during the 4th quarter worth approximately $39,000.

Wall Street Analyst Weigh In

Several research firms have weighed in on STVN. UBS Group dropped their target price on shares of Stevanato Group from $24.00 to $23.50 and set a "neutral" rating for the company in a report on Friday, March 7th. Bank of America lifted their price objective on Stevanato Group from $24.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, December 13th. Morgan Stanley reiterated an "equal weight" rating and set a $23.00 target price (down previously from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. Wolfe Research began coverage on Stevanato Group in a report on Friday, December 13th. They issued an "outperform" rating and a $28.00 price target for the company. Finally, William Blair reaffirmed an "outperform" rating on shares of Stevanato Group in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of €27.75 ($29.84).

Remove Ads

Stevanato Group Trading Down 4.9 %

Shares of NYSE:STVN traded down €1.09 ($1.17) during midday trading on Tuesday, reaching €21.26 ($22.86). The company's stock had a trading volume of 345,197 shares, compared to its average volume of 347,661. The firm has a market cap of $6.44 billion, a price-to-earnings ratio of 45.23, a price-to-earnings-growth ratio of 7.18 and a beta of 0.60. The business has a 50 day moving average price of €21.04 and a 200 day moving average price of €20.59. Stevanato Group S.p.A. has a 1 year low of €16.56 ($17.81) and a 1 year high of €33.49 ($36.01). The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22.

Stevanato Group (NYSE:STVN - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) EPS for the quarter, meeting analysts' consensus estimates of €0.20 ($0.22). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The company had revenue of €352.68 million during the quarter, compared to the consensus estimate of €346.26 million. Research analysts forecast that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.